Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor vs. Prasugrel Effects on Infarct Size
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Yochai Birnbaum
- Registration Number
- NCT02507323
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Memorial Hermann Hospital, Houston, Texas, United States
🇺🇸Baylor-St. Lukes Medical Center, Houston, Texas, United States
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 180
- Registration Number
- NCT02505399
- Locations
- 🇫🇷
Clinique Pasteur, Toulouse, Haute-Garonne, France
🇫🇷University Hospital, Nîmes, France
🇫🇷Hospices civils de Lyon, Lyon, France
Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02487732
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT02486367
- Locations
- 🇺🇸
UH Cleveland Medical Center, Cleveland, Ohio, United States
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2022-06-09
- Target Recruit Count
- 5225
- Registration Number
- NCT02484924
- Locations
- 🇬🇧
University Hospital Aintree, Liverpool, United Kingdom
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT02482298
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- University Hospital of Limerick
- Target Recruit Count
- 61
- Registration Number
- NCT02469740
- Locations
- 🇮🇪
University Hospital Limerick, Dooradoyle, Limerick, Ireland
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Spanish Society of Cardiology
- Target Recruit Count
- 30
- Registration Number
- NCT02457130
- Locations
- 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
🇪🇸Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Hellenic Cardiovascular Research Society
- Target Recruit Count
- 336
- Registration Number
- NCT02429271
- Locations
- 🇬🇷
General Hospital of Heraklion Venizeleio-Pananeio, Heraklion, Crete, Greece
Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 110
- Registration Number
- NCT02422888
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.